Supplementary Figure S8 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy | Synapse
October 2, 2025Open Access
Supplementary Figure S8 from Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy
Key Points
Blocking NRF2 translation increases lymphoma cell sensitivity to ferroptosis and improves CAR T-cell therapy outcomes.
In vivo tumor growth studies reveal that zotatifin enhances the efficacy of CAR T immunotherapy in lymphoma models.
CAR T cell co-culture assays confirm the synergistic effect of targeting NRF2 translation alongside CAR T-cell treatment.
These findings suggest a promising therapeutic strategy for lymphoma by combining zotatifin with immunotherapy.
Abstract
CAR T cell co-culture assays and in vivo tumor growth studies assessing the synergy of zotatifin with CAR T immunotherapy.